EP Patent
EP3191461B1 — Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
Assigned to Pfizer Inc · Expires 2021-11-03 · 5y expired
What this patent protects
Patent listed against Vyndaqel.
Drugs covered by this patent
- Vyndaqel (Tafamidis Meglumine) · Foldrx Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.